BioSpace· Jennifer C. Smith-Parker·· 4 hours agoPickScore35
More arms, more questions: The new challenge in multispecific drug design
In brief
Multispecific drugs are evolving from bispecifics to trispecifics, T-cell engagers with co-stimulation, NK engagers and dual agonists. Each added binding arm multiplies the number of possible combinations, and the focus of development has shifted from candidate discovery to candidate selection.
Why it matters
Multispecific formats are proliferating and candidate selection is growing more complex.
Source: BioSpace